

VICURON PHARMACEUTICALS INC
Form 8-K
March 19, 2004

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported):

March 17, 2004

Vicuron Pharmaceuticals Inc.

Edgar Filing: VICURON PHARMACEUTICALS INC - Form 8-K

(Exact Name of Registrant As Specified in its Charter)

Delaware
(State or Other Jurisdiction

000-31145
(Commission

04-3278032
(I.R.S. Employer

of Incorporation)

File Number)

Identification Number)

455 South Gulph Road, King of Prussia, PA 19406

(Address of Principal Executive Offices) (Zip Code)

(610) 205-2300

(Registrant's telephone number, including area code)

(Former Name or Former Address, if Changed Since Last Report.)

ITEM 5. OTHER EVENTS.

On March 17, 2004, in a letter addressed to Vicuron Pharmaceuticals Inc. (the Company), Claudio Quarta, Ph.D. resigned as Chief Operating Officer of the Company as of March 19, 2004. There were no disagreements between Dr. Quarta and the Company on any matter relating to the Company's operations, policies or practices.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

VICURON PHARMACEUTICALS INC.

(Registrant)

Date: March 19, 2004

By: /S/ GEORGE F. HORNER III

George F. Horner III
President and Chief Executive Officer